



April 06, 2021

Listing Department,
National Stock Exchange of India Limited
Exchange Plaza, Plot C-1, Block G,
Bandra Kurla Complex,
Bandra (E),
MUMBAI - 400 051
Symbol: MAXHEALTH

Listing Department,
BSE Limited
25th Floor,
Phiroze Jeejeebhoy Towers,
Dalal Street,
MUMBAI - 400 001
Scrip Code: 543220

Sub: Intimation of proposed formation of a wholly owned subsidiary company

Dear Sir / Ma'am,

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations"), we would like to inform that the Board of Directors of the Company at their meeting held today, have approved the incorporation of a wholly owned subsidiary (WOS) of the Company (i.e. Max Healthcare Institute Ltd.), to *inter-alia* provide range of diagnostic services including pathology lab services to retail and non-captive customers as well as third party Hospital Lab Management.

The details required under regulation 30 of the Listing Regulations read with SEBI Circular No. CIR/CFD/CMD 1412015 dated September 9, 2015 are enclosed as Annexure A.

Submitted for your information and records.

Thanking you,
For Max Healthcare Institute Limited

Ruchi Mahajan
Company Secretary & Compliance Officer

Annexure A
Details of wholly owned subsidiary proposed to be incorporated

Sr. No.	Particulars	Details
1.	Name of the target entity, details in brief such as size, turnover etc.	<ul style="list-style-type: none"> • Max Lab Limited/ Max Laboratories Limited/ Max Path Limited and / or any other name as may be approved by the Ministry of Corporate Affairs; • Proposed Authorized Share Capital: INR 20 Crores (Indian Rupees Twenty Crores only) comprising of 2 crores equity shares of INR 10 each; • Proposed Paid up Share Capital: INR 5 Crores (Indian Rupees Five Crores only) comprising of 50 lakh equity shares of INR 10 each; • Turnover: Not applicable (the wholly owned subsidiary (“WOS”) is yet to be incorporated).
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”	<ul style="list-style-type: none"> • The WOS company once incorporated will be a related party of the Company; • None of the promoter/promoter group/ group companies is interested in this transaction.
3.	Industry to which the entity being acquired belongs	Healthcare Service Provider
4.	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	The WOS is being incorporated to <i>inter-alia</i> provide range of diagnostic services including pathology lab services to retail and non-captive customers as well as third party Hospital Lab Management.
5.	Brief details of any governmental or regulatory approvals required for the acquisition	Not applicable.

6.	Indicative time period for completion of the acquisition	Not applicable
7.	Nature of consideration - whether cash consideration or share swap and details of the same	100% subscription to the share capital in cash
8.	Cost of acquisition or the price at which the shares are acquired	Cost of acquisition is INR 5 Crores (50 lakh equity shares of INR 10 each in one or more tranches)
9.	Percentage of shareholding / control acquired and / or number of shares acquired	100%
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	Not applicable, since the WOS is yet to be incorporated